Remove Clinical Development Remove Targeted Protein Degradation Remove Therapies
article thumbnail

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

The companies will equally share worldwide development costs, commercialization expenses, and profits. This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer.

article thumbnail

Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules

The Pharma Data

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. In this process, protein-degrading molecules ‘co-opt’ large cellular proteins (ubiquitin ligases) to breakdown other target proteins, including those that cause cancer. “We

article thumbnail

A New Wave of Therapeutic Innovation Through Targeting Transcription Factors

LifeSciVC

However, in recent years, huge leaps have been made in drug discovery ranging from novel technologies unearthing new techniques for small molecule development to new modalities like targeted protein degradation that are beginning to open the door to a promising wave of transcription factor-directed therapeutic candidates.